7-methoxy-2-carboxy-2,3-dihydro-1,4-benzodioxin | 177351-41-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 7-methoxy-2-carboxy-2,3-dihydro-1,4-benzodioxin
• 英文别名: 6-Methoxy-2,3-dihydro-1,4-benzodioxine-3-carboxylic acid
• CAS: 177351-41-6
• 化学式: C₁₀H₁₀O₅
• 分子量: 210.186
• InChiKey: SRCAUFJCQKNYRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  372.3±42.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-methoxy-2-carboxy-2,3-dihydro-1,4-benzodioxin 在 palladium on activated charcoal 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 氢气 、 三溴化硼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 APTS 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-羟甲基-1,4-苯并二恶烷
  参考文献：
  名称：

  Synthesis of enantiomerically pure 7-hydroxy-2-substituted-2,3-dihydro-1,4-benzodioxin derivatives

  摘要：

  A rapid and simple procedure for the preparation of the two pure enantiomers of 7-hdroxy-2-substituted-2,3-dihydro-1,4-benzodioxin derivatives is described.

  DOI：

  10.1016/0957-4166(94)80011-1
• 作为产物：
  描述：

  1,4-苯并二氧六环-2-甲酸乙酯 在 盐酸 、 氢氧化钾 、 三氯化铝 、 间氯过氧苯甲酸 作用下， 以 二硫化碳 为溶剂， 反应 18.0h， 生成 7-methoxy-2-carboxy-2,3-dihydro-1,4-benzodioxin
  参考文献：
  名称：

  Synthesis of enantiomerically pure 7-hydroxy-2-substituted-2,3-dihydro-1,4-benzodioxin derivatives

  摘要：

  A rapid and simple procedure for the preparation of the two pure enantiomers of 7-hdroxy-2-substituted-2,3-dihydro-1,4-benzodioxin derivatives is described.

  DOI：

  10.1016/0957-4166(94)80011-1

文献信息

• [EN] N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES<br/>[FR] DÉRIVÉS DE N-(4-(OXAZOL-5-YL) PHÉNYL)CHROMANE-3-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QUE STIMULATEURS DE LA PRODUCTION DE CELLULES PRÉCURSEURS RÉTINIENNES POUR LE TRAITEMENT DE MALADIES NEURORÉTINIENNES
  申请人：ENDOGENA THERAPEUTICS INC

  公开号：WO2020140050A1

  公开（公告）日：2020-07-02

  New compounds and to a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, comprising administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a is selected from the group consisting of a 5-oxazolyl, a pyridine-4-yl, a triazolyl, a oxadiazolyl, a imidazolyl and a 2-methyloxazol-5-yl residue, R1, and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) wherein, II*II denotes the point of attachment to the remainder of the molecule, and R2, R3, R4, R5, R2 I, R3 I, R4 I, R5 I, R2 II, R3 II R4 II, R5 II, R2 III, R3 III, R4 III, R5 III, R2 IV, R3 IV, R4 IV, R5 IV, R2 V, R3 V, R4 V, R5 V , R2 VI, R3 VI, R4 VI, R5 VI,R2 VII, R3 VII, R4 VII, R5 VII, are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, 2,2,2-trifluoromethyl and difluoromethoxy.

  新化合物及治疗导致光感受器丧失或外视网膜退化的视网膜疾病的方法，包括给予式(I)的化合物或其药学上可接受的盐、消旋混合物、相应对映体或如适用的话，相应的二对映体，其中：A选自由5-噁唑基、吡啶-4-基、三唑基、噁二唑基、咪唑基和2-甲氧基噁唑-5-基残基的群组，R1和R12独立选自氢、氟、氯、甲氧基、三氟甲基、甲基和二氟甲氧基的群组，B选自式(II)、(III)、(IV)、(V)、(VI)、(VII)、(VIII)和(IX)的残基的群组，其中，II*II表示与分子其余部分的连接点，R2、R3、R4、R5、R2 I、R3 I、R4 I、R5 I、R2 II、R3 II、R4 II、R5 II、R2 III、R3 III、R4 III、R5 III、R2 IV、R3 IV、R4 IV、R5 IV、R2 V、R3 V、R4 V、R5 V、R2 VI、R3 VI、R4 VI、R5 VI、R2 VII、R3 VII、R4 VII、R5 VII独立选自氢、具有1至3个碳原子的直链或支链烷基、氟、氯、溴、甲氧基、乙氧基、丙氧基、2,2,2-三氟甲基和二氟甲氧基的群组。
• Compounds for use as therapeutically active substances in the treatment of retinal diseases
  申请人：ENDOGENA THERAPEUTICS, INC.

  公开号：US10807973B2

  公开（公告）日：2020-10-20

  New compounds and a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, including administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a 5-oxazolyl residue or a pyridine-4-yl residue, R1 is selected from the group consisting of fluoro, chloro and methoxy; B is selected from the group consisting of a residue of formula (II), (III) and (IV) wherein, “*” denotes the point of attachment to the remainder of the molecule, and R2, R2′, R2″, R3, R3′, R3″, R4, R4′, R4″, R5, R5′ and R5″ are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 4 carbon atoms, trifluoromethyl, 2,2,2-trifluoroethyl, methylsulfanyl, ethylsulfanyl, methylsulfonyl, ethylsulfonyl, difluoromethoxy, trifluoromethoxy, fluoro, bromo, chloro, methoxy, ethoxy, propoxy, butoxy, hydroxy and amino.

  治疗导致光感受器缺失或视网膜外层变性的视网膜疾病的新化合物和方法，包括施用式（I）化合物 或其药学上可接受的盐、外消旋混合物、相应的对映体或（如适用）相应的非对映异构体，其中：A 是 5-恶唑基残基或吡啶-4-基残基，R1 选自氟、氯和甲氧基组成的组； B 选自式（II）、（III）和（IV）残基组成的组 其中，"*"表示与分子其余部分的连接点，R2、R2′、R2″、R3、R3′、R3″、R4、R4′、R4″、R5、R5′和R5″独立地选自氢组成的组、具有 1 至 4 个碳原子的直链或支链烷基、三氟甲基、2,2,2-三氟乙基、甲硫基、乙硫基、甲磺酰基、乙磺酰基、二氟甲氧基、三氟甲氧基、氟、溴、氯、甲氧基、乙氧基、丙氧基、丁氧基、羟基和氨基。
• Khouili; Guillaumet; Coudert, Il Farmaco, 1996, vol. 51, # 3, p. 185 - 188
  作者：Khouili、Guillaumet、Coudert、Pujol

  DOI：——

  日期：——
• (3<i>R</i>)-4,4-Dimethyl-2-oxotetrahydrofuran-3-yl (<i>2S</i>)-7-methoxy-2,3-dihydro-1,4-benzodioxin-2-carboxylate
  作者：M. Khouili、M. D. Pujol、X. Solans、M. Font-Bardia、A. Souizi、G. Coudert、G. Guillaumet

  DOI：10.1107/s0108270198013900

  日期：1999.3.15

  The structure of the title compound, C16H18O7, a key intermediate in the synthesis of antagonist adrenergic agents, is reported. The 1,4-benzodioxin ring shows a half-chair form with a Csp(3) atom out of the plane defined by the remaining atoms. The lactone ring shows an envelope form.
• N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES
  申请人：Endogena Therapeutics, Inc.

  公开号：EP3902798A1

  公开（公告）日：2021-11-03